Xeris Biopharma Holdings, Inc. provided earnings guidance for the year 2024. The momentum continues in 2024 as the company expects to grow total revenue in the range of $170 million to $200 million. This double-digit revenue growth, coupled with recent debt refinancing and continued disciplined cash management, will allow the company to further invest in all aspects of business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.255 USD | +1.12% | +16.84% | -4.04% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 334M | |
+40.73% | 739B | |
+31.18% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.77% | 240B | |
+9.39% | 210B | |
-5.11% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024